CLIR vs. NAUT, PRE, INTT, OPXS, ODYS, AKYA, OMIC, OPTX, AATC, and DAIO
Should you be buying ClearSign Technologies stock or one of its competitors? The main competitors of ClearSign Technologies include Nautilus Biotechnology (NAUT), Prenetics Global (PRE), inTEST (INTT), Optex Systems (OPXS), Odysight.ai (ODYS), Akoya Biosciences (AKYA), Singular Genomics Systems (OMIC), Syntec Optics (OPTX), Autoscope Technologies (AATC), and Data I/O (DAIO). These companies are all part of the "measuring and control equipment" industry.
ClearSign Technologies vs. Its Competitors
Nautilus Biotechnology (NASDAQ:NAUT) and ClearSign Technologies (NASDAQ:CLIR) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
ClearSign Technologies has higher revenue and earnings than Nautilus Biotechnology. ClearSign Technologies is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nautilus Biotechnology and Nautilus Biotechnology both had 2 articles in the media. Nautilus Biotechnology's average media sentiment score of 0.94 equaled ClearSign Technologies'average media sentiment score.
50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 24.0% of ClearSign Technologies shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 5.0% of ClearSign Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nautilus Biotechnology has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, ClearSign Technologies has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Nautilus Biotechnology presently has a consensus target price of $2.13, indicating a potential upside of 171.91%. ClearSign Technologies has a consensus target price of $2.00, indicating a potential upside of 270.37%. Given ClearSign Technologies' stronger consensus rating and higher possible upside, analysts plainly believe ClearSign Technologies is more favorable than Nautilus Biotechnology.
Nautilus Biotechnology has a net margin of 0.00% compared to ClearSign Technologies' net margin of -216.48%. Nautilus Biotechnology's return on equity of -31.87% beat ClearSign Technologies' return on equity.
Summary
Nautilus Biotechnology beats ClearSign Technologies on 7 of the 13 factors compared between the two stocks.
Get ClearSign Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearSign Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:CLIR) was last updated on 7/12/2025 by MarketBeat.com Staff
Free CLIR Stock Alerts